Sunitinib Induced Hypocalcemia and its Potential Role in the Treatment of Refractory Hypercalcemia

Authors:
Notice: Undefined offset: 0 in /home/medwincom/public_html/article-description.php on line 436

DOI: 10.23880/oaje-16000105

Volume 1, Issue 1

Abstract

Background: Sunitinib, an oral multi-targeted tyrosine kinase inhibitor has been approved for the treatment of advanced pancreatic neuroendocrine neoplasms (pNENs). Aim: To describe a series of 12 patients with pNENs on sunitinib who developed hypocalcemia. Patients and Methods: Three patients developed hypocalcemia, grade 4, 1 and 2 respectively. Results: A 58-year-old man with a stage IV, grade 2, initially non-functioning pNEN (NFpNEN), developed disease progression with concomitant hypersecretion of parathyroid hormone related-peptide (PTHrP) and uncontrolled hypercalcemia. After one month of sunitinib treatment, grade 4 hypocalcemia (

Keywords: <p>Sunitinib; Hypocalcemia; Pancreatic Neuroendocrine Neoplasm; Tyrosine Kinase Inhibitors</p>

View PDF